TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells

[1]  C. Croce,et al.  Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. , 2014, Journal of the National Cancer Institute.

[2]  Xiaohong Xu,et al.  Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. , 2014, Cancer research.

[3]  Heng Zhao,et al.  TRAF6 promoted the tumorigenicity of esophageal squamous cell carcinoma , 2013, Tumor Biology.

[4]  B. Koller,et al.  The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB , 2012, Nature Immunology.

[5]  S. Lam,et al.  TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer. , 2011, The Journal of clinical investigation.

[6]  G. Krissansen,et al.  Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer. , 2010, Cancer letters.

[7]  Peter Olson,et al.  Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. , 2010, Cancer cell.

[8]  A. Sood,et al.  Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells , 2008, Clinical Cancer Research.

[9]  C. Heldin,et al.  The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner , 2008, Nature Cell Biology.

[10]  R. Berardi,et al.  COX-2 and NF-KB Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin , 2007, American journal of clinical oncology.

[11]  W. Weichert,et al.  High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis , 2007, British Journal of Cancer.

[12]  N. Chandler,et al.  Increased expression of NF-κB subunits in human pancreatic cancer cells1,2 ☆ , 2004 .

[13]  R. Cardiff,et al.  Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase , 2003, International journal of cancer.

[14]  A. Arlt,et al.  Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death , 2003, Oncogene.

[15]  B. Evers,et al.  Inflammation and the development of pancreatic cancer. , 2002, Surgical oncology.

[16]  David Baltimore,et al.  Inducibility of κ immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism , 1986, Cell.

[17]  E. Giovannetti,et al.  Role of CYB5A in pancreatic cancer prognosis and autophagy modulation. , 2014, Journal of the National Cancer Institute.

[18]  G. La Torre,et al.  A Systematic Review of Resectability and Survival After Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer , 2009, Annals of Surgical Oncology.

[19]  Douglas B. Evans,et al.  Function of nuclear factor kappaB in pancreatic cancer metastasis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Douglas B. Evans,et al.  Function of Nuclear Factor κB in Pancreatic Cancer Metastasis , 2003 .

[21]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .

[22]  A. Baldwin,et al.  The NF-kappa B and I kappa B proteins: new discoveries and insights. , 1996, Annual review of immunology.

[23]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[24]  D. Baltimore,et al.  Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. , 1986, Cell.